Cell And Gene Therapy Companies Fear More Market Delays From EU’s Single Review Plans
Regulations Aimed At Streamlining Could Make Things Worse
Executive Summary
Biopharma fears that the Joint Clinical Assessment, a first step to harmonizing health technology assessments in the EU, is not fit for purpose for cell and gene therapies and will increase rather than eliminate market access delays.